– Clinical study confirms safety, feasibility, and tolerability of the Everads Injector– – Preclinical data demonstrate the feasibility of in-office, minimally invasive suprachoroidal buckling using the Everads Injector to repair retinal detachments – Everads Therapy, a clinical-stage company leveraging its novel suprachoroidal delivery technology to advance the treatment of retinal diseases, today announced two oral presentations…
Kwame Marfo brings more than 15 years of experience at the intersection of life sciences, health technology, and product innovation Unlearn®, a leader in AI solutions for clinical trials, today announced the appointment of Kwame Marfo as its Vice President of Product. Marfo’s appointment solidified Unlearn’s trajectory, as it continues to scale and advance its…
Anervea to Build Breakthrough ClinDev Optimization Suite on Komodo’s MapLab Enterprise, Harnessing Real-World Data and AI to Accelerate Market Access and Improve Patient Outcomes Komodo Health, the Evidentiary Standard for real-world patient-journey insights and healthcare analytics, today announced a strategic partnership with Anervea.ai, an AI-native Life Sciences technology company, to accelerate innovation across Clinical Development….
Anervea to Build Breakthrough ClinDev Optimization Suite on Komodo’s MapLab Enterprise, Harnessing Real-World Data and AI to Accelerate Market Access and Improve Patient Outcomes Komodo Health, the Evidentiary Standard for real-world patient-journey insights and healthcare analytics, today announced a strategic partnership with Anervea.ai, an AI-native Life Sciences technology company, to accelerate innovation across Clinical Development….
Powering Alzheimer’s research with AI-driven insights across cognition, meaning, motor function, and speech — accelerating study recruitment and enabling more equitable, personalized brain health care Linus Health, which is revolutionizing brain health with science-driven digital solutions, will present two oral presentations and eight posters at the Alzheimer’s Association International Conference® (AAIC®) 2025, taking place July 27-31 in Toronto and virtually. Linus Health…
Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases. This effort, known as the Louisiana AI Drug Development Infrastructure for ALS (LADDIA), brings together leading institutions and innovators, including GATC Health, Pennington Biomedical Research Center, and Tulane University — a tech-bio innovator…
From target discovery to trial optimization, bfLEAP empowers biopharma teams to predict therapeutic success with greater confidence In a $200B+ market crowded with black-box AI, BullFrog AI’s bfLEAP delivers what others can’t: biologically grounded, composition-aware analytics that guide smarter therapeutic decisions BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug…
Real-world data (RWD), artificial intelligence (AI), and patient-centric trial design lead pharma priorities in 2025, but data compatibility, regulatory hurdles, and security concerns threaten to stall momentum. As biopharmaceutical companies double down on innovation and patient-centric research, a new industry survey from studioID and TriNetX reveals widespread integration of RWD and AI in drug development…
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara…
The deal pairs San Juan, Puerto Rico site’s deep community ties, top-tier enrollment, and 90% retention with Headlands’ network-wide infrastructure and resources to accelerate clinical research Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of CMRCenter (CMRC), a high-performing clinical research site in San Juan, Puerto Rico. The deal expands Headlands’ footprint…